We found that the combination of alpelisib and eribulin significantly reduced the migratory and invasive capacity of paclitaxel-resistant as well as parental PIK3CA-mutated endometrial cancer cells (Figure 4E and Supplementary Figure S3A). Here, PIK3CA is linked to endometrial cancer.